P/B
1,1
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.
$292.5M
Market Cap • 9/18/2026
2021
(5 years)
Founded
2024
(2 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
92,6
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
5
EPS
—
Market Cap
Market Cap
292,5M
EV
32,1M
EV/Revenue
10,2
EV/EBITDA
-0,2
EV/EBIT
-0,2
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-1,7%
Total Yield
-1,7%
Payout
0%
Retained Earnings
-414,5M
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
4616,8%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
0,5%
% Goodwill
0%
ROE
—
ROIC
—
Leverage
N.D./EBITDA
1,5
Debt/Equity
0%
Current Ratio
28
Quick Ratio
26,2
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!